ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly total research and development expense ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Operations & Segment Footnote
Latest, FY2025
13,337
Period ended Dec 31, 2025
Change on a year earlier
+21.3%
10,991 in FY2024
History
19 years
Since FY2007
Sources
13
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total research and development expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13,337 | +21.3% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 10,991 | +18.0% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 9,313 | +29.5% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 7,191 | +3.8% | Form 10-K (filed 2025-02-19) ↗ |
| FY2021 | Dec 31, 2021 | 6,931 | +16.0% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 5,976 | +6.8% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 5,595 | +10.8% | Form 10-K (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 5,051 | -0.9% | Form 10-K (filed 2020-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 5,096 | -4.0% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 5,310 | +10.7% | Form 10-K (filed 2019-02-19) ↗ |
| FY2015 | Dec 31, 2015 | 4,796 | +1.3% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 4,734 | -14.4% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 5,531 | +4.8% | Form 10-K (filed 2014-02-19) ↗ |
| FY2012 | Dec 31, 2012 | 5,278 | +5.1% | Form 10-K (filed 2013-02-21) ↗ |
| FY2011 | Dec 31, 2011 | 5,021 | +2.8% | Form 10-K (filed 2012-02-24) ↗ |
| FY2010 | Dec 31, 2010 | 4,884 | +12.9% | Form 10-K (filed 2011-02-22) ↗ |
| FY2009 | Dec 31, 2009 | 4,327 | +12.6% | Form 10-K (filed 2010-02-22) ↗ |
| FY2008 | Dec 31, 2008 | 3,841 | +10.2% | Form 10-K (filed 2010-02-22) ↗ |
| FY2007 | Dec 31, 2007 | 3,487 | – | Form 10-K (filed 2010-02-22) ↗ |
Breakdown
What makes up total research and development expense ($m)
Cite this data
StockData. (2026). Eli Lilly Total research and development expense ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rd_exp_total
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.